Head and Neck Cancer Therapies: Current and Innovative Options

Dear Colleagues,

The HNSCC therapeutic landscape is currently in a state of high-stakes flux. While we celebrate the "immunotherapy revolution," the bedside reality remains tethered to the toxicities of decades-old regimens. This Special Issue seeks to host a rigorous dialog on innovation, interrogating the following:

• LA-HNSCC Neoadjuvant Pivots: Does the surge in perioperative immunotherapy truly redefine organ preservation, or does the disconnect between pathologic complete response (pCR) and surgical margin safety pose new clinical risks?
• Molecular Warheads and Dual Targeting: Beyond simple inhibition, how are ADCs managing the delicate balance between bystander effects and off-target payload toxicities? Are bispecific antibodies effectively achieving dual-pathway inhibition without the prohibitive adverse events seen in early-phase trials?
• The HPV Paradox: Refining de-intensification—moving from "can we do less?" to "how do we do less safely?"
• Underserved Malignancies: We turn our focus lastly—but crucially—to salivary gland cancers and sinonasal carcinomas, where therapeutic breakthroughs have historically lagged behind.

Dr. Ye Guo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.